| Symbol | GRCE |
|---|---|
| Name | GRACE THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 103 CARNEGIE CENTER,SUITE 300, PRINCETON, H7E 2B5, Canada |
| Telephone | 818-839-4378 |
| Fax | — |
| — | |
| Website | https://www.gracetx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001444192 |
| Description | Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The companys lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey. Additional info from NASDAQ: |
(10% Negative) GRACE THERAPEUTICS, INC. (GRCE) Announces Clinical Trial Timeline Adjustment
Read moreNew Form SCHEDULE 13G/A - Grace Therapeutics, Inc. <b>Filed:</b> 2026-04-27 <b>AccNo:</b> 0001493152-26-019071 <b>Size:</b> 9 KB
Read more(90% Positive) GRACE THERAPEUTICS, INC. (GRCE) Provides Update on data for a resubmission of its NDA
Read moreGrace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
Read moreGrace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07237295 | CommunityRx-Kidney Health | Na | Chronic Kidney Disease (Stages 1-4) | Recruiting | 2026-04-13 | 2028-06-01 | ClinicalTrials.gov |
| NCT06199531 | Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency | Phase3 | NGLY1 Deficiency | Active_Not_Recruiting | 2024-02-13 | 2031-03-01 | ClinicalTrials.gov |
| NCT05849844 | Tympanoseal Clinical Study | Na | Tympanic Membrane Perforation | Recruiting | 2024-01-05 | 2026-04-20 | ClinicalTrials.gov |
| NCT05995405 | Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients wi… | Phase3 | Aneurysmal Subarachnoid Hemorrhage (aSAH) | Active_Not_Recruiting | 2023-10-20 | 2024-12-01 | ClinicalTrials.gov |
| NCT06122766 | NGLY1 Natural History | — | NGLY1 Deficiency | Completed | 2023-02-27 | 2024-10-24 | ClinicalTrials.gov |
| NCT05531890 | Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-1… | Phase1 | Ataxia Telangiectasia | Unknown | 2022-09-13 | 2023-05-03 | ClinicalTrials.gov |
| NCT05517486 | Single-dose to Evaluate the Pharmacokinetics of GTX-101 and Subcutaneous Inject… | Phase1 | Postherpetic Neuralgia | Unknown | 2022-07-26 | 2023-05-03 | ClinicalTrials.gov |
| NCT05418348 | Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Cap… | Phase1 | Aneurysmal Subarachnoid Hemorrhage | Completed | 2021-08-26 | 2022-02-24 | ClinicalTrials.gov |
| NCT03814681 | Postopoperarive Outcomes After Colorectal Surgery in Europe (euroPOWER) | — | Perioperative Care | Unknown | 2019-09-15 | 2020-01-15 | ClinicalTrials.gov |
| NCT03834987 | NGLY1 Deficiency: A Prospective Natural History Study | — | Genetic Syndrome | Terminated | 2019-02-01 | 2021-11-19 | ClinicalTrials.gov |
| NCT03361501 | A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2) | Phase3 | Hypertriglyceridemia | Completed | 2018-02-01 | 2020-01-09 | ClinicalTrials.gov |
| NCT03398005 | A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1) | Phase3 | Hypertriglyceridemia | Completed | 2018-01-23 | 2019-11-20 | ClinicalTrials.gov |
| NCT01516151 | Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-h… | Phase2 | Hypertriglyceridemia | Completed | 2011-12-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01455844 | TRIal For Efficacy of Capre on hyperTriglyceridemiA | Phase2 | Hypertriglyceridemia | Completed | 2011-09-01 | 2014-08-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| GS-100 | Other | Phase PHASE3 | NGLY1 Deficiency | ACTIVE_NOT_RECRUITING | NCT06199531 |
| GS-100 | Other | Phase PHASE3 | NGLY1 Deficiency | ACTIVE_NOT_RECRUITING | NCT06199531 |
| GS-100 | Other | Phase PHASE3 | NGLY1 Deficiency | ACTIVE_NOT_RECRUITING | NCT06199531 |
| GS-100 | Other | Phase PHASE3 | NGLY1 Deficiency | ACTIVE_NOT_RECRUITING | NCT06199531 |
| GS-100 | Other | Phase PHASE3 | NGLY1 Deficiency | ACTIVE_NOT_RECRUITING | NCT06199531 |
| GS-100 | Other | Phase PHASE3 | NGLY1 Deficiency | ACTIVE_NOT_RECRUITING | NCT06199531 |
| GS-100 | Other | Phase PHASE3 | NGLY1 Deficiency | ACTIVE_NOT_RECRUITING | NCT06199531 |
| GS-100 | Other | Phase PHASE3 | NGLY1 Deficiency | ACTIVE_NOT_RECRUITING | NCT06199531 |
| GS-100 | Other | Phase PHASE3 | NGLY1 Deficiency | ACTIVE_NOT_RECRUITING | NCT06199531 |
| GS-100 | Other | Phase PHASE3 | NGLY1 Deficiency | ACTIVE_NOT_RECRUITING | NCT06199531 |
| GS-100 | Other | Phase PHASE3 | NGLY1 Deficiency | ACTIVE_NOT_RECRUITING | NCT06199531 |
| Lipid Lowering Medication | Drug | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT01516151 |
| CaPre™ | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT01516151 |
| Placebo | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT01455844 |
| CaPre (TM) | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT01455844 |
| Colorectal Surgery | Procedure | Preclinical | Perioperative Care | UNKNOWN | NCT03814681 |
| Placebo | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT03398005 |
| CaPre | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT03398005 |
| Placebo | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT03361501 |
| CaPre | Other | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT03361501 |
| Neurodevelopmental Assessment | Other | Preclinical | Genetic Syndrome | TERMINATED | NCT03834987 |
| Betamethasone Oral Solution Period 1 and Period 2 | Other | Phase PHASE1 | Ataxia Telangiectasia | UNKNOWN | NCT05531890 |
| Betamethasone solution as intramuscular injection Period 1 and Period 2 | Other | Phase PHASE1 | Ataxia Telangiectasia | UNKNOWN | NCT05531890 |
| GTX-102 low dose fast Period 1 and Period 2 | Other | Phase PHASE1 | Ataxia Telangiectasia | UNKNOWN | NCT05531890 |
| GTX-102 high dose fast Period 1 and Period 2 | Other | Phase PHASE1 | Ataxia Telangiectasia | UNKNOWN | NCT05531890 |
| GTX-102 medium dose slow Period 1 and Period 2 | Other | Phase PHASE1 | Ataxia Telangiectasia | UNKNOWN | NCT05531890 |
| GTX-102 medium dose fast Period 1 and Period 2 | Other | Phase PHASE1 | Ataxia Telangiectasia | UNKNOWN | NCT05531890 |
| Bupivacaine HCl subcutaneous injection | Other | Phase PHASE1 | Postherpetic Neuralgia | UNKNOWN | NCT05517486 |
| GTX-101 | Other | Phase PHASE1 | Postherpetic Neuralgia | UNKNOWN | NCT05517486 |
| Nimodipine Capsules | Other | Phase PHASE1 | Aneurysmal Subarachnoid Hemorrhage | COMPLETED | NCT05418348 |
| GTX-104 | Other | Phase PHASE1 | Aneurysmal Subarachnoid Hemorrhage | COMPLETED | NCT05418348 |
| Nimotop 30 MG Oral Capsule | Other | Phase PHASE3 | Aneurysmal Subarachnoid Hemorrhage (aSAH) | ACTIVE_NOT_RECRUITING | NCT05995405 |
| GTX-104 | Other | Phase PHASE3 | Aneurysmal Subarachnoid Hemorrhage (aSAH) | ACTIVE_NOT_RECRUITING | NCT05995405 |
| Tympanoseal | Other | Approved | Tympanic Membrane Perforation | RECRUITING | NCT05849844 |
| CommunityRx-Kidney Health | Other | Approved | Chronic Kidney Disease (Stages 1-4) | RECRUITING | NCT07237295 |
| CommunityRx-Kidney Health | Other | Approved | Chronic Kidney Disease (Stages 1-4) | RECRUITING | NCT07237295 |
| CommunityRx-Kidney Health | Other | Approved | Chronic Kidney Disease (Stages 1-4) | RECRUITING | NCT07237295 |
| CommunityRx-Kidney Health | Other | Approved | Chronic Kidney Disease (Stages 1-4) | RECRUITING | NCT07237295 |
| CommunityRx-Kidney Health | Other | Approved | Chronic Kidney Disease (Stages 1-4) | RECRUITING | NCT07237295 |
| CommunityRx-Kidney Health | Other | Approved | Chronic Kidney Disease (Stages 1-4) | RECRUITING | NCT07237295 |
| CommunityRx-Kidney Health | Other | Approved | Chronic Kidney Disease (Stages 1-4) | RECRUITING | NCT07237295 |
| Nimotop 30 MG Oral Capsule | DRUG | Phase PHASE3 | Aneurysmal Subarachnoid Hemorrhage (aSAH) | ACTIVE_NOT_RECRUITING | NCT05995405 |
| Betamethasone Oral Solution Period 1 and Period 2 | DRUG | Phase PHASE1 | Ataxia Telangiectasia | UNKNOWN | NCT05531890 |
| Betamethasone solution as intramuscular injection Period 1 and Period 2 | DRUG | Phase PHASE1 | Ataxia Telangiectasia | UNKNOWN | NCT05531890 |
| GTX-102 low dose fast Period 1 and Period 2 | DRUG | Phase PHASE1 | Ataxia Telangiectasia | UNKNOWN | NCT05531890 |
| GTX-102 high dose fast Period 1 and Period 2 | DRUG | Phase PHASE1 | Ataxia Telangiectasia | UNKNOWN | NCT05531890 |
| GTX-102 medium dose slow Period 1 and Period 2 | DRUG | Phase PHASE1 | Ataxia Telangiectasia | UNKNOWN | NCT05531890 |
| GTX-102 medium dose fast Period 1 and Period 2 | DRUG | Phase PHASE1 | Ataxia Telangiectasia | UNKNOWN | NCT05531890 |
| Bupivacaine HCl subcutaneous injection | DRUG | Phase PHASE1 | Postherpetic Neuralgia | UNKNOWN | NCT05517486 |
| GTX-101 | DRUG | Phase PHASE1 | Postherpetic Neuralgia | UNKNOWN | NCT05517486 |
| Nimodipine Capsules | DRUG | Phase PHASE1 | Aneurysmal Subarachnoid Hemorrhage | COMPLETED | NCT05418348 |
| GTX-104 | DRUG | Phase PHASE3 | Aneurysmal Subarachnoid Hemorrhage (aSAH) | ACTIVE_NOT_RECRUITING | NCT05995405 |
| CaPre | DRUG | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT03398005 |
| Lipid Lowering Medication | DRUG | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT01516151 |
| Placebo | DRUG | Phase PHASE3 | Hypertriglyceridemia | COMPLETED | NCT03398005 |
| CaPre (TM) | DRUG | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT01455844 |